Understanding the Connection between Nanoparticle Uptake and Cancer Treatment Efficacy using Mathematical Modeling

Sci Rep. 2018 May 24;8(1):7538. doi: 10.1038/s41598-018-25878-8.

Abstract

Nanoparticles have shown great promise in improving cancer treatment efficacy while reducing toxicity and treatment side effects. Predicting the treatment outcome for nanoparticle systems by measuring nanoparticle biodistribution has been challenging due to the commonly unmatched, heterogeneous distribution of nanoparticles relative to free drug distribution. We here present a proof-of-concept study that uses mathematical modeling together with experimentation to address this challenge. Individual mice with 4T1 breast cancer were treated with either nanoparticle-delivered or free doxorubicin, with results demonstrating improved cancer kill efficacy of doxorubicin loaded nanoparticles in comparison to free doxorubicin. We then developed a mathematical theory to render model predictions from measured nanoparticle biodistribution, as determined using graphite furnace atomic absorption. Model analysis finds that treatment efficacy increased exponentially with increased nanoparticle accumulation within the tumor, emphasizing the significance of developing new ways to optimize the delivery efficiency of nanoparticles to the tumor microenvironment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Biological Availability
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Cell Line, Tumor
  • Doxorubicin / administration & dosage
  • Doxorubicin / pharmacokinetics
  • Drug Delivery Systems
  • Female
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Models, Theoretical*
  • Nanoparticles* / administration & dosage
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Neoplasms / pathology
  • Pharmacokinetics*
  • Tissue Distribution
  • Tumor Burden
  • Xenograft Model Antitumor Assays

Substances

  • Doxorubicin